TrialDrug design, development and therapy2024

Safety, Tolerability and Pharmacokinetics of Intravenous Sodium Taurodeoxycholate, HY209, a GPCR19 Agonist Inhibiting Inflammasomal Activation.

Woo Kyung Chung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.